Abstract: The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.
Type:
Application
Filed:
February 16, 2005
Publication date:
December 7, 2006
Applicant:
Government of the USA, as represented by the Secretary Department of Health & Human Services
Inventors:
Mary Stracke, Lance Liotta, Elliott Schiffmann, Henry Krutzch, Jun Murata
Abstract: The disclosure encompasses p28TEV polypeptide, polynucleotides, variants, and antagonists. p28TEV polypeptides and/or polynucleotides are useful in immunogenic compositions. p28TEV polypeptide antagonists include antagonist antibodies, antisense molecules or siRNA molecules. The antagonists and composition of the disclosure can be administered alone or in combination with other agents useful in the treatment of HIV infection, SIV infection, AIDS, or AIDS-related complex (ARC), including nucleoside, non-nucleoside, and/or reverse transcriptase inhibitors.
Type:
Application
Filed:
February 27, 2006
Publication date:
September 14, 2006
Applicant:
The Government of the USA, as represented by the Secretary, Department of Health and Human Services
Inventors:
Miroslav Dundr, Genoveffa Franchini, Jake Fullen
Abstract: The invention provides an isolated or purified ribonucleic acid (RNA) molecule comprising a nucleotide sequence encoded by a human (Tey1) metastasis suppressor gene located at p21-p12 on chromosome 8 or a fragment thereof, wherein the isolated or purified RNA molecule comprises from about 10 to about 100 nucleotides. The invention also provides methods of diagnosis, prognosis, and treatment of cancer, such as prostate cancer, using the isolated or purified RNA molecule.
Type:
Application
Filed:
July 26, 2005
Publication date:
July 6, 2006
Applicant:
GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
J. Barrett, Naoki Nihei, Natalay Kouprina, Vladimir Larionov
Abstract: The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.
Type:
Application
Filed:
April 26, 2005
Publication date:
September 8, 2005
Applicant:
The Government of the USA, as represented by the Secretary, Department of Health and Human Services
Inventors:
Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
Abstract: The present invention relates, e.g., to a method for generating and analyzing multi-factorial biological response profiles, comprising (a) exposing each member of a plurality of expression control sequences, each of which is operatively linked to a heterologous reporter sequence, independently, to at least about three stimuli from a first set of stimuli, wherein at least about two of the stimuli in said first set of stimuli are, optionally, combined in an intra-set combinatorial fashion; (b) detecting a first category of responses of said expression control sequences to said stimuli; and (c) generating a response profile for each of said expression control sequences.
Type:
Application
Filed:
April 12, 2004
Publication date:
July 14, 2005
Applicant:
Government of the USA, as represented by the secretary, Department of Health and Human Services
Abstract: Disclosed are methods of using 7?,11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7?,11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate, and processes for its preparation.
Type:
Application
Filed:
January 21, 2005
Publication date:
June 16, 2005
Applicant:
Government of the USA, represented by the Secretary, Department of Health and Human Services
Abstract: The present invention provides an aspartic proteinase-inhibiting compound of the formula: wherein a, b, c, d, and e, can be the same or different and each are R7, OR7, SR7, NR7R7, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen, wherein R7 and R8 are independently H or an alkyl. Substituents R1 or R2 are each H or an alkyl. Substituent R3 is a straight chain or branched alkyl, alkenyl, or alkynyl substituent, or is a cycloalkyl. Substituent A is OH, NH2, or SH. Further provided are pharmaceutical compositions, which include a therapeutically effective amount of at least one of the foregoing compounds, and therapeutic methods of using the foregoing compounds.
Type:
Application
Filed:
June 11, 2003
Publication date:
April 28, 2005
Applicant:
Government of the USA, represented by the Secretary, Department of Health and Human Services
Inventors:
Ramnarayan Randad, John Erickson, Michael Eissenstat, Lucyna Lubkowska
Abstract: The present invention provides a method of targeting transient gene expression and stable gene expression from the exogenous administration of a DNA sequence, which sequence is less than a complete genome, wherein said DNA sequence encodes RNA and protein, or RNA only, to differentiate tissue of living organisms wherein said DNA sequence through a jet injector technique, and said DNA sequence of less than a complete genome is expressed in a living organism. The present invention further provides a flexible multi-nozzle injector device with a wide surface area to allow molding of the injector nozzle to the surface contours of the tissue. Another aspect of the present invention provides an injection device having a long nozzle for injection of DNA deep into the host tissue. Also, in a further aspect the present invention provides an injector device. modified to be used with and/or inject through an endoscopic device.
Type:
Application
Filed:
January 20, 2004
Publication date:
September 30, 2004
Applicant:
Government of the USA, represented by the Secretary, Department of Health and Human Services
Inventors:
Priscilla Anne Furth, Lothar Hennighausen
Abstract: The present invention discloses the isolation of the human and murine wild-type Int6 gene and the cDNAs sorresponding to these genes. The invention further describes the use of reagents derived from the nucleic acid and amino acid sequences of the Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines.
Type:
Application
Filed:
February 19, 2004
Publication date:
July 22, 2004
Applicant:
The Government of the USA as represented by the Secretary, Department of Health and Human Services
Inventors:
Antonio Marchetti, Fiamma Buttitta, Gilbert H. Smith, Robert Callahan
Abstract: Particularly sensitive techniques for the detection of P. carinii in clinical samples are disclosed. These techniques relate to the PCR amplification and/or detection of human-P. carinii major surface glycoprotein (MSG) gene sequences. Also disclosed are seven novel genes encoding human-P. carinii MSG, and the proteins encoded for by these genes. These genes provide proof that human-P. carinii MSG is encoded for by a highly conserved gene family, and that the corresponding proteins have a very highly conserved region of about 100 amino acids near their C-terminal end. This highly conserved carboxy-terminal region has a significantly different sequence than that found in rat-derived MSG.
Type:
Application
Filed:
September 2, 2003
Publication date:
March 4, 2004
Applicant:
The Government of the USA represented by Secretary of the Department of Health & Human Services
Inventors:
Joseph A. Kovacs, Shengning Huang, Henry Masur, Steven H. Fischer, Vee J. Gill, Qin Mei
Abstract: The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation.
Type:
Application
Filed:
July 22, 2002
Publication date:
December 5, 2002
Applicant:
The Government of USA, as represented by the Secretary, Department of Health and Human Services